sage-718 sage-718 sage-718 is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment. it acts as a positive allosteric modulator of the nmda receptor, whose activity is essential for learning, memory, and cognition. sage-718 is an analog of the neurosteroid 24s-hydroxycholesterol. sage-718legal statuslegal status investigational identifiers iupac name (3s,8r,9s,10r,13r,14s,17r)-3,13-dimethyl-17--2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopentaphenanthren-3-ol cas number2311911-06-3pubchem cid134452289chemical and physical dataformulac26h41f3o2molar mass442.607 g·mol−1 as of 2022, sage-718 is in phase ii clinical trials for alzheimer's disease, parkinson's disease, and huntington's disease.